Andere Sprachen SCD Co., Ltd.

Aktien

A042110

KR7042110007

A042110

Schlusskurs Korea S.E. Andere Börsenplätze 00:00:00 17.05.2024			% 5 Tage	% 1. Jan.
1’531 ^KRW	-0.58%		+2.41%	-12.66%

03.04.	Schroder European Real Estate Investment Trust refinanziert ein Darlehen in Höhe von 9 Millionen Euro	MT
01.02.	SeaStar Medical erhält kanadisches Patent für Technologie zur zellgesteuerten Therapie	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Schroder European Real Estate Investment Trust Refinances EUR9 Million Loan	03.04.
SeaStar Medical Gets Canadian Patent Covering Technology for Cell-Directed Therapy	01.02.
Pfizer : va présenter de nouvelles données en hématologie	03.11.
SeaStar Medical's Selective Cytopheretic Device Considered Approvable by the US FDA for Pediatric AKI and Sepsis Treatment	03.10.23
Schroder European Real Estate Investment Trust Posts Lower Property Portfolio Valuation as of June 30	17.07.23
Schroder European Real Estate Investment Trust Swings to Fiscal H1 Loss	28.06.23
SCD Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15.05.23
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	10.05.23
SeaStar Medical Holding Shares Drop After US FDA Rejects Application for Pediatric Selective Cytopheretic Device	10.05.23
Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group	13.04.23
Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group	12.04.23
Schroder European Real Estate Investment Trust Posts Lower FY22 NAV	23.03.23
Schroder European Real Estate Investment Trust Buys EUR11 Million Warehouse in Netherlands	20.03.23
China Fines Five Banks 388 Million Yuan Over Irregularities	20.02.23
SeaStar Medical Shares Rise 20% After FDA Grants IDE Application	09.02.23
National Bank Begins Coverage on Lycos Energy	19.12.22
Pfizer : finalise l'acquisition de Global Blood Therapeutics	05.10.22
Graphite Bio Gets Fast Track Designation for GPH101 Sickle Cell Treatment	03.05.22
Editas Medicine Secures FDA Rare Pediatric Disease Designation for EDIT-301 for Beta Thalassemia	26.04.22
Global Blood Therapeutics's Oxbryta Gets European Approval for Treatment of Hemolytic Anemia in Patients With SCD	16.02.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen SCD Co., Ltd.

Aktien

A042110

KR7042110007

A042110

Andere Sprachen

Filter